SEC Company Response from BRAINSTORM CELL THERAPEUTICS (BCLI) — Jun 1, 2026
BRAINSTORM CELL THERAPEUTICS INC.
Date: June 1, 2026 · CIK: 0001137883 · Accession: 0001104659-26-068906
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296090
Letter
Brainstorm Cell Therapeutics, Inc.
1325 Avenue of Americas, 28th Floor
New York, New York 10019
(201) 488-0460
June 1, 2026
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Re: Brainstorm Cell Therapeutics Inc.
Registration Statement on Form S-1
SEC File No. 333-296090
Request for Acceleration
To whom it may concern:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Brainstorm Cell Therapeutics Inc. (the " Company ") hereby requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-296090) (the " Registration Statement ") be accelerated so that the Company's Registration Statement will become effective at 5:00 P.M., eastern time, on June 2, 2026, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Thompson Hine LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Thompson Hine LLP, by calling Faith L. Charles at (212) 908-3905.
Please feel free to direct any questions or comments concerning this request to Faith L. Charles of Thompson Hine LLP at (212) 908-3905.
BRAINSTORM CELL THERAPEUTICS INC.
By: /s/ Chaim Lebovits
Name: Chaim Lebovits
Title: President and Chief Executive Officer
Cc: Faith L. Charles, Thompson Hine LLP
Show Raw Text
CORRESP 1 filename1.htm Brainstorm Cell Therapeutics, Inc. 1325 Avenue of Americas, 28th Floor New York, New York 10019 (201) 488-0460 June 1, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Brainstorm Cell Therapeutics Inc. Registration Statement on Form S-1 SEC File No. 333-296090 Request for Acceleration To whom it may concern: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Brainstorm Cell Therapeutics Inc. (the " Company ") hereby requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-296090) (the " Registration Statement ") be accelerated so that the Company's Registration Statement will become effective at 5:00 P.M., eastern time, on June 2, 2026, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Thompson Hine LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Thompson Hine LLP, by calling Faith L. Charles at (212) 908-3905. Please feel free to direct any questions or comments concerning this request to Faith L. Charles of Thompson Hine LLP at (212) 908-3905. BRAINSTORM CELL THERAPEUTICS INC. By: /s/ Chaim Lebovits Name: Chaim Lebovits Title: President and Chief Executive Officer Cc: Faith L. Charles, Thompson Hine LLP